IDEAYA Biosciences (IDYA) Other Non-Current Liabilities (2018 - 2021)
IDEAYA Biosciences (IDYA) posted Other Non-Current Liabilities of $6000.0 for Q3 2021, little changed sequentially from $6000.0 in Q2 2021, and down 50.0% YoY from $12000.0 in Q3 2020.
IDEAYA Biosciences (IDYA) Other Non-Current Liabilities (2018 - 2021) Analysis & Trends
IDEAYA Biosciences has reported Other Non-Current Liabilities for 4 years, with the latest figure at $6000.0 in Q3 2021.
- Quarterly Other Non-Current Liabilities fell 50.0% year-over-year to $6000.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $6000.0 (down 50.0% YoY) and the FY2020 annual result came in at $12000.0, down 64.71% from the prior year.
- Other Non-Current Liabilities was little changed at $6000.0 in Q3 2021 per IDYA's latest filing, from $6000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $113000.0 in Q4 2018 and troughed at $6000.0 in Q2 2021.
- A 4-year average of $29142.9 and a median of $12000.0 in 2020 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2019 and 2021: Other Non-Current Liabilities sank 69.91% in 2019, then plunged 50.0% in 2021.
- Over 4 years, Other Non-Current Liabilities stood at $113000.0 in 2018, then tumbled by 69.91% to $34000.0 in 2019, then plunged by 64.71% to $12000.0 in 2020, then slumped by 50.0% to $6000.0 in 2021.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $6000.0, $6000.0, and $12000.0 for Q3 2021, Q2 2021, and Q4 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 6,000.00 |
| Jun 30, 2021 | 6,000.00 |
| Dec 31, 2020 | 12,000.00 |
| Sep 30, 2020 | 12,000.00 |
| Mar 31, 2020 | 21,000.00 |
| Dec 31, 2019 | 34,000.00 |
| Dec 31, 2018 | 113,000.00 |